Actively Recruiting
Evaluating Tonlamarsens Effectiveness and Safety in Adults Recently Hospitalized with Acute Severe Hypertension A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study
Led by Kardigan, Inc. · Updated on 2026-10-15
140
Participants Needed
13
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating tonlamarsen, an investigational drug designed to reduce blood pressure by blocking the bodys production of the protein angiotensinogen AGT in the liver. The study focuses on adults recently hospitalized due to acute severe hypertension, including hypertensive emergency and urgency, to assess tonlamarsens blood pressure-lowering effects and safety compared to a placebo. Participants will receive either tonlamarsen or a placebo through subcutaneous injections once every four weeks, for a total of three doses over approximately three months. The study is randomized, double-blind, and placebo-controlled, with two parallel groups receiving either the active drug or placebo. The research includes two parts, with assessments of blood AGT levels and blood pressure at multiple time points, including weeks 4 and 12. During the study, participants will visit the clinic about seven times for initial evaluations, checkups, tests, and follow-up assessments. Researchers will monitor blood pressure, measure plasma AGT levels, and evaluate safety and tolerability throughout the study period. The primary outcomes focus on changes in AGT and blood pressure, and participants will be followed for safety up to week 36. The total study duration spans from screening through the last follow-up visit.
CONDITIONS
Brief Title
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
Research Team
K
Kardigan Clinical Study Information Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here